181 related articles for article (PubMed ID: 37775689)
21. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
22. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
[No Abstract] [Full Text] [Related]
23. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
Front Oncol; 2021; 11():810023. PubMed ID: 35223458
[TBL] [Abstract][Full Text] [Related]
24. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
Breast Cancer Res Treat; 2023 Aug; 201(1):105-115. PubMed ID: 37310540
[TBL] [Abstract][Full Text] [Related]
25. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
26. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
27. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
Tolaney SM; Sahebjam S; Le Rhun E; Bachelot T; Kabos P; Awada A; Yardley D; Chan A; Conte P; Diéras V; Lin NU; Bear M; Chapman SC; Yang Z; Chen Y; Anders CK
Clin Cancer Res; 2020 Oct; 26(20):5310-5319. PubMed ID: 32694159
[TBL] [Abstract][Full Text] [Related]
28. Retrospective registry of patients with locally advanced/metastatic HR
Chavarría Piudo N; Blancas I; González Flores E; Henao Carrasco F; López Álvarez P; Morales Pancorbo D; Gámez Casado S; Lomas Garrido MC; Rodríguez García JM; Martínez Guisado A; Sánchez Vega A; Ruíz Borrego M
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38831191
[TBL] [Abstract][Full Text] [Related]
29. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
[TBL] [Abstract][Full Text] [Related]
30. Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
Blanch S; Gil-Gil JM; Arumí M; Aguirre E; Seguí MÁ; Atienza M; Díaz-Cerezo S; Molero A; Cervera JM; Gavilá J
Clin Transl Oncol; 2023 Oct; 25(10):2950-2959. PubMed ID: 37029241
[TBL] [Abstract][Full Text] [Related]
31. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
32. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
33. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study.
Li D; Jin Y; Lin M; Zeng C; Guo Q; Liu Y; Zhang J
Cancer Med; 2024 Feb; 13(4):e6762. PubMed ID: 38457252
[TBL] [Abstract][Full Text] [Related]
35. Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.
Matos E; Cankar K; Režun N; Dejanović K; Ovčariček T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791907
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract][Full Text] [Related]
39. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
40. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
